en001
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 18, 2022 (NCT05338099)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Streptococcus pneumoniaeINHIBITOR
Streptococcus pneumoniae inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06328712 | Phase 1 | Mar 31, 2024 | ENCell |
| NCT06328725 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2024 | ENCell |
| NCT05333406 | Phase 1 | Feb 22, 2022 | ENCell |
| NCT05338099 | Phase 1 | Jan 18, 2022 | ENCell |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ENCell | For profit | 4 | 4 | 2 | 2022 |
1 organizations
Page 1 / 1